Prakash Chandra Gupta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Prakash Chandra Gupta has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Nisha Sharma
Chhatrapati Shahu Ji Maharaj University
11 shared publications- Nisha Sharma
School of Pharmaceutical Sciences, Chhatrapati Shahu Ji Maharaj University, Kalyanpur, Kanpur, Uttar Pradesh 208024, India
5 shared publications Priyanka Mishra
Department of Pharmaceutical Sciences School of Pharmaceutical and Biological Sciences HBTU Kanpur Uttar Pradesh India
5 shared publicationsSweta Rai
Chhatrapati Shahu Ji Maharaj University
4 shared publicationsZeeshan Ansari
4 shared publicationsAshish Verma
3 shared publications
Latest Publications
- 16 October 2026
- Published by Springer Nature
- p. 1-28
Life Cycle Assessment of Nanomaterials in Environmental Applications
- 16 October 2026
- Published by Springer Nature
- p. 1-28
Life Cycle Assessment of Nanomaterials in Environmental Applications
- Open Access
- 4 August 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (30) , e74046
Repurposing Drugs and Phytochemicals in Leishmaniasis Therapy: Emerging Strategies and Translational Potential
Leishmaniasis, a vector‐borne disease caused by protozoan parasites of the genus Leishmania , is a significant global challenge, particularly in resource‐constrained areas. The treatment of leishmaniasis has remained stagnant for over 70 years since the discovery of pentavalent antimonials (SbV), with no novel antileishmanial drugs developed during this period, reflecting limited engagement from academia and the pharmaceutical industry. Numerous FDA‐approved and investigational pharmaceuticals, initially designed for cancer, fungal, viral, or inflammatory disorders, have encouraging antileishmanial efficacy. The recent clinical landscape highlights that all three new treatments—amphotericin‐B, paromomycin, and miltefosine—are repurposed drugs rather than novel compounds. The current antileishmanial drug pipeline is notably sparse, with LXE 408 as the only candidate progressing to phase II clinical trials. Only two emerging candidates (DNDI‐6174 and ChAd63‐KH vaccine) are ready for preclinical/clinical studies. This scenario underscores an urgent need for drug repurposing strategies to accelerate the availability of effective therapies. Concurrently, phytotherapy offers promising adjunctive or alternative options due to the bioactive potential of plant‐derived compounds, as demonstrated by varying antileishmanial activities against different Leishmania species. Integrating drug repurposing with phytotherapeutic approaches could address the gaps in treatment options and combat species‐specific drug susceptibilities, thereby enhancing therapeutic outcomes in leishmaniasis management.
- 4 August 2026
- Published by Wiley in ChemistrySelect
- Vol. 11 (30) , e74046
Open AccessRepurposing Drugs and Phytochemicals in Leishmaniasis Therapy: Emerging Strategies and Translational Potential
Leishmaniasis, a vector‐borne disease caused by protozoan parasites of the genus Leishmania , is a significant global challenge, particularly in resource‐constrained areas. The treatment of leishmaniasis has remained stagnant for over 70 years since the discovery of pentavalent antimonials (SbV), with no novel antileishmanial drugs developed during this period, reflecting limited engagement from academia and the pharmaceutical industry. Numerous FDA‐approved and investigational pharmaceuticals, initially designed for cancer, fungal, viral, or inflammatory disorders, have encouraging antileishmanial efficacy. The recent clinical landscape highlights that all three new treatments—amphotericin‐B, paromomycin, and miltefosine—are repurposed drugs rather than novel compounds. The current antileishmanial drug pipeline is notably sparse, with LXE 408 as the only candidate progressing to phase II clinical trials. Only two emerging candidates (DNDI‐6174 and ChAd63‐KH vaccine) are ready for preclinical/clinical studies. This scenario underscores an urgent need for drug repurposing strategies to accelerate the availability of effective therapies. Concurrently, phytotherapy offers promising adjunctive or alternative options due to the bioactive potential of plant‐derived compounds, as demonstrated by varying antileishmanial activities against different Leishmania species. Integrating drug repurposing with phytotherapeutic approaches could address the gaps in treatment options and combat species‐specific drug susceptibilities, thereby enhancing therapeutic outcomes in leishmaniasis management.
- 1 July 2026
- Published by Bentham Science Publishers Ltd. in Current Women s Health Reviews
- Vol. 22 (5) , 1-16
Diagnosis and Management of Thyroid Dysfunction in Postpartum Women: A Narrative Review
Introduction: Postpartum thyroid dysfunction (PPTD), particularly postpartum thyroiditis, is a prevalent yet under recognized endocrine disorder affecting women within the first year after childbirth. It may present as transient hyperthyroidism, hypothyroidism, or both, and up to 20–30% of cases progress to permanent hypothyroidism. Immune system modulation during and after pregnancy, especially in women with thyroid peroxidase (TPO) antibodies, plays a central role in its pathogenesis. Methods: This article presents a narrative overview of recent literature published over the past 10 years. Relevant sources were identified through searches in scientific databases such as PubMed, Scopus, Web of Science, and Google Scholar. Results: Emerging tools (liquid biopsy, molecular imaging, next-generation sequencing) and AI algorithms enhance early detection. Targeted screening is recommended for high-risk women, particularly those with autoimmune thyroid disease or TPO antibodies. Therapeutic strategies include selenium/ iodine supplementation, hormone replacement, and immunomodulatory agents. Telemedicine shows potential for individualized care. Discussion: Our findings indicate that PPTD remains underdiagnosed (5-10% prevalence) despite clear autoimmune involvement (60% TPOAb-positive). Symptom overlap with normal postpartum recovery and inconsistent screening protocols contribute to diagnostic delays. While novel tools show diagnostic potential, their validation remains incomplete. The 20-30% progression to permanent hypothyroidism warrants targeted screening and personalized management. Future studies should optimize screening cost-effectiveness and evaluate long-term child development outcomes. Conclusion: Despite advancements, PPTD diagnosis remains challenging due to non-specific symptoms. A multidisciplinary approach integrating emerging technologies and public health initiatives is essential. Future research should focus on predictive models and long-term prevention strategies.
- 1 July 2026
- Published by Bentham Science Publishers Ltd. in Current Women s Health Reviews
- Vol. 22 (5) , 1-16
Diagnosis and Management of Thyroid Dysfunction in Postpartum Women: A Narrative Review
Introduction: Postpartum thyroid dysfunction (PPTD), particularly postpartum thyroiditis, is a prevalent yet under recognized endocrine disorder affecting women within the first year after childbirth. It may present as transient hyperthyroidism, hypothyroidism, or both, and up to 20–30% of cases progress to permanent hypothyroidism. Immune system modulation during and after pregnancy, especially in women with thyroid peroxidase (TPO) antibodies, plays a central role in its pathogenesis. Methods: This article presents a narrative overview of recent literature published over the past 10 years. Relevant sources were identified through searches in scientific databases such as PubMed, Scopus, Web of Science, and Google Scholar. Results: Emerging tools (liquid biopsy, molecular imaging, next-generation sequencing) and AI algorithms enhance early detection. Targeted screening is recommended for high-risk women, particularly those with autoimmune thyroid disease or TPO antibodies. Therapeutic strategies include selenium/ iodine supplementation, hormone replacement, and immunomodulatory agents. Telemedicine shows potential for individualized care. Discussion: Our findings indicate that PPTD remains underdiagnosed (5-10% prevalence) despite clear autoimmune involvement (60% TPOAb-positive). Symptom overlap with normal postpartum recovery and inconsistent screening protocols contribute to diagnostic delays. While novel tools show diagnostic potential, their validation remains incomplete. The 20-30% progression to permanent hypothyroidism warrants targeted screening and personalized management. Future studies should optimize screening cost-effectiveness and evaluate long-term child development outcomes. Conclusion: Despite advancements, PPTD diagnosis remains challenging due to non-specific symptoms. A multidisciplinary approach integrating emerging technologies and public health initiatives is essential. Future research should focus on predictive models and long-term prevention strategies.
- 10 February 2026
- Published by Taylor & Francis
- p. 283-302
Flowers in Mental Health
- 10 February 2026
- Published by Taylor & Francis
- p. 170-180
Pharmacology, Phytochemistry, and Medicinal Use of Echinacea (Echinacea Purpurea)
- 10 February 2026
- Published by Taylor & Francis
- p. 170-180
Pharmacology, Phytochemistry, and Medicinal Use of Echinacea (Echinacea Purpurea)
- 1 November 2025
- Published by Springer Nature
- p. 157-181
Use of Copper-Based Nanomaterials in Postharvest Management
- 1 November 2025
- Published by Springer Nature
- p. 157-181
Use of Copper-Based Nanomaterials in Postharvest Management
- 22 August 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 20 (5) , 1-17
A Promising Approach to Target Cancer for Anticancer Drug Delivery via Engineered Cubosomal Nanocarriers
Carcinoma is a worldwide concern of well-being that leads health concern leading to mor-tality and disability. Although current treatment procedures offer some efficacy, they are not devoid of constraints and potential adverse reactions. Over the past few years, tremendous progress has emerged in newer strategies like immunotherapy and novel drug delivery systems, such as designing formula-tions utilising utilizing non-lamellar liquid-crystalline nanoparticles, known as lyotropic systems. Among them, cubosomes are one of the distinct categories of nanocarriers, formed by utilising utilizing precise proportions of amphiphilic lipids. Cubosomes are known for their ability to be compatible with living organisms and their flexibility in transporting drugs, allowing for the administration of pharma-ceuticals through many pathways. Several preclinical investigations have been reported to explore the future of cubosomes in cancer therapy and theranostic applications. The findings suggest that nano-technology and cancer therapies like immunotherapy have significant potential for tailored and effi-cient treatment approaches. Cubosomes can offer a promising contribution to the discipline of cancer research and the goal of enhancing therapeutic innovations. However, extensive research is required to confirm the safety, drug release mechanism, and stability of these nanocarriers. It covers a brief overview of cancer therapy including immunotherapy, advantages of targeted drug delivery, general aspects on of cubosomes, types of cubosomes, structural components, and preparation methods, fol-lowed by the mechanism of release, and discoveries on cubosomes as drug delivery for various cancers covering breast, colorectal, lung, liver, cervical, skin, etc. along with the future perspectives of other novel therapies like immunology in cancer.
- 22 August 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Therapy
- Vol. 20 (5) , 1-17
A Promising Approach to Target Cancer for Anticancer Drug Delivery via Engineered Cubosomal Nanocarriers
Carcinoma is a worldwide concern of well-being that leads health concern leading to mor-tality and disability. Although current treatment procedures offer some efficacy, they are not devoid of constraints and potential adverse reactions. Over the past few years, tremendous progress has emerged in newer strategies like immunotherapy and novel drug delivery systems, such as designing formula-tions utilising utilizing non-lamellar liquid-crystalline nanoparticles, known as lyotropic systems. Among them, cubosomes are one of the distinct categories of nanocarriers, formed by utilising utilizing precise proportions of amphiphilic lipids. Cubosomes are known for their ability to be compatible with living organisms and their flexibility in transporting drugs, allowing for the administration of pharma-ceuticals through many pathways. Several preclinical investigations have been reported to explore the future of cubosomes in cancer therapy and theranostic applications. The findings suggest that nano-technology and cancer therapies like immunotherapy have significant potential for tailored and effi-cient treatment approaches. Cubosomes can offer a promising contribution to the discipline of cancer research and the goal of enhancing therapeutic innovations. However, extensive research is required to confirm the safety, drug release mechanism, and stability of these nanocarriers. It covers a brief overview of cancer therapy including immunotherapy, advantages of targeted drug delivery, general aspects on of cubosomes, types of cubosomes, structural components, and preparation methods, fol-lowed by the mechanism of release, and discoveries on cubosomes as drug delivery for various cancers covering breast, colorectal, lung, liver, cervical, skin, etc. along with the future perspectives of other novel therapies like immunology in cancer.
- Top Cited Papers
- 29 May 2025
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 84, 120-134
Exploring inflammatory and fibrotic mechanisms driving diabetic nephropathy progression
- 29 May 2025
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 84, 120-134
Top Cited PapersExploring inflammatory and fibrotic mechanisms driving diabetic nephropathy progression
- Top Cited Papers
- 4 April 2025
- Published by Elsevier in Microbial Pathogenesis
- Vol. 204, 107535
Comprehensive insights into leishmaniasis: From etiopathogenesis to a novel therapeutic approach
- 4 April 2025
- Published by Elsevier in Microbial Pathogenesis
- Vol. 204, 107535
Top Cited PapersComprehensive insights into leishmaniasis: From etiopathogenesis to a novel therapeutic approach
- 24 January 2025
- Published by Springer Nature
- p. 21-44
Properties and Synthesis of Chitin-Based Nanoparticles
- 24 January 2025
- Published by Springer Nature
- p. 21-44
Properties and Synthesis of Chitin-Based Nanoparticles